Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia

Daniele Roberto Giacobbe, Alessio Signori, Mario Tumbarello, Riccardo Ungaro, Giovanni Sarteschi, Elisa Furfaro, Malgorzata Mikulska, Maurizio Sanguinetti, Brunella Posteraro, Angela Raffaella Losito, Gennaro De Pascale, Valerio Del Bono, Claudio Viscoli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32–68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27–20.10) and 12.50% (95% CI 12.16–12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.

Original languageEnglish
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Candidemia
Observational Studies
Costs and Cost Analysis
Therapeutics
Communicable Diseases
Intensive Care Units
Sepsis
Prospective Studies

Keywords

  • Biomarker
  • Candidemia
  • Diagnosis
  • DOOR
  • Glucan

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. / Giacobbe, Daniele Roberto; Signori, Alessio; Tumbarello, Mario; Ungaro, Riccardo; Sarteschi, Giovanni; Furfaro, Elisa; Mikulska, Malgorzata; Sanguinetti, Maurizio; Posteraro, Brunella; Losito, Angela Raffaella; De Pascale, Gennaro; Del Bono, Valerio; Viscoli, Claudio.

In: European Journal of Clinical Microbiology and Infectious Diseases, 01.01.2018.

Research output: Contribution to journalArticle

@article{f968343e0e3d4fbd9bb86d7cea4cb466,
title = "Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia",
abstract = "Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81{\%} (95{\%} CI 67.32–68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68{\%} (95{\%} CI 19.27–20.10) and 12.50{\%} (95{\%} CI 12.16–12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.",
keywords = "Biomarker, Candidemia, Diagnosis, DOOR, Glucan",
author = "Giacobbe, {Daniele Roberto} and Alessio Signori and Mario Tumbarello and Riccardo Ungaro and Giovanni Sarteschi and Elisa Furfaro and Malgorzata Mikulska and Maurizio Sanguinetti and Brunella Posteraro and Losito, {Angela Raffaella} and {De Pascale}, Gennaro and {Del Bono}, Valerio and Claudio Viscoli",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10096-018-3441-1",
language = "English",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",

}

TY - JOUR

T1 - Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia

AU - Giacobbe, Daniele Roberto

AU - Signori, Alessio

AU - Tumbarello, Mario

AU - Ungaro, Riccardo

AU - Sarteschi, Giovanni

AU - Furfaro, Elisa

AU - Mikulska, Malgorzata

AU - Sanguinetti, Maurizio

AU - Posteraro, Brunella

AU - Losito, Angela Raffaella

AU - De Pascale, Gennaro

AU - Del Bono, Valerio

AU - Viscoli, Claudio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32–68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27–20.10) and 12.50% (95% CI 12.16–12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.

AB - Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32–68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27–20.10) and 12.50% (95% CI 12.16–12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.

KW - Biomarker

KW - Candidemia

KW - Diagnosis

KW - DOOR

KW - Glucan

UR - http://www.scopus.com/inward/record.url?scp=85057780513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057780513&partnerID=8YFLogxK

U2 - 10.1007/s10096-018-3441-1

DO - 10.1007/s10096-018-3441-1

M3 - Article

AN - SCOPUS:85057780513

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

ER -